Matt joined OUP in 2013 and focuses on investments in therapeutics, diagnostics, medical devices, and research tools. He has been involved with OUP’s investment in several portfolio companies including Kura Oncology (NASDAQ: KURA), Spero Therapeutics (NASDAQ: SPRO), Cell Design Labs (acquired by Gilead), Biohaven Pharma (NYSE: BHVN), Arrakis Therapeutics, Antiva Biosciences, PMV Pharma, and others. Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, healthcare, and private equity. Engagements included strategy development, market assessment, commercialization support, portfolio development, acquisition target identification, and diligence / transaction support. As a Ph.D. student at the University of Pennsylvania Matt conducted research on the antibody response to a novel protein-based poxvirus vaccine and advised several startups while working with the Penn Biotech Group.
Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University.